Analytes of Interest and Choice of Dose Two Important Considerations in the Design of Bioequivalence Studies With Atorvastatin Jbb.1000060
Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857) Mary McHale, Sam Abel, Deborah Russell, James Gallagher, Elna van der Ryst.
Answer
Overview of Phase 1 and 2a Safety and Efficacy Data of Maraviroc (UK-427,857)
